AH Bio Fund II, L.P.
SEC Form 4 insider trading activity
AH Bio Fund II, L.P. has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jul 29, 2026.
On the most recent filing, AH Bio Fund II, L.P. is listed as 10% Owner at Scribe Therapeutics, Inc. Inside the rolling window, AH Bio Fund II, L.P. reported 1 open-market purchase totaling $5.0M in SCTX and no open-market sales.
Companies traded
Other insiders at SCTX
Insider Buying
$5.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has AH Bio Fund II, L.P. made?
AH Bio Fund II, L.P. has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company since 2026.
Which companies does AH Bio Fund II, L.P. trade?
AH Bio Fund II, L.P. has filed SEC Form 4 disclosures for 1 company, including SCTX.
When was AH Bio Fund II, L.P.'s most recent SEC Form 4 filing?
AH Bio Fund II, L.P.'s most recent SEC Form 4 filing on Tracefour is dated Jul 29, 2026.
What is AH Bio Fund II, L.P.'s total buy and sell value in the current window?
Inside the rolling retention window, AH Bio Fund II, L.P. bought $5.0M and sold $0 based on SEC Form 4 filings.
What was AH Bio Fund II, L.P.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 333,333 SCTX shares on 2026-07-27, worth $5.0M, per SEC Form 4 filings.